Associated Papers
The effect of cisplatin on cytotoxicity of anticancer cytokine TRAIL and its receptor-selective mutant variant DR5-B1.
Gasparian ME et al.
Doklady. Biochemistry and Biophysics, 2017
Decreased affinity of recombinant human tumor necrosis factor-related apoptosis-inducing ligand (rhTRAIL) D269H/E195R to osteoprotegerin (OPG) overcomes TRAIL resistance mediated by the bone microenvironment.
Bosman MC et al.
The Journal of Biological Chemistry, 2014
Combination of TRAIL with bortezomib shifted apoptotic signaling from DR4 to DR5 death receptor by selective internalization and degradation of DR4.
Bychkov ML et al.
Plos One, 2014
DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
Yu R et al.
Cancer Biology & Therapy, 2014
Delivery of sTRAIL variants by MSCs in combination with cytotoxic drug treatment leads to p53-independent enhanced antitumor effects.
Yu R et al.
Cell Death & Disease, 2013
Targeting AML through DR4 with a novel variant of rhTRAIL.
Szegezdi E et al.
Journal of Cellular and Molecular Medicine, 2011
DR4-selective tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) variants obtained by structure-based design.
Tur V et al.
The Journal of Biological Chemistry, 2008
Select a paper to view details